Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07624513 · ClinicalTrials.gov registry record · Phase 3
Determination 2 - Isatuximab, Iberdomide, Bortezomib and Dexamethasone Induction, Followed by Risk- and Response-Adapted Consolidation and Maintenance Therapy, in Transplant-Eligible Patients With Newly Diagnosed Multiple Myeloma
A Phase 3 study, sponsored by Dana-Farber Cancer Institute.
- Not yet
- Registry status
- Phase 3
- Development phase
- 720
- Enrollment target
NCT07624513 is a Phase 3 study that has not yet begun recruiting, run by Dana-Farber Cancer Institute. The registered enrollment target is 720 participants.
The verdict
NCT07624513, a Phase 3 study, has not yet begun recruiting, sponsored by Dana-Farber Cancer Institute.
- NOT YET RECRUITING
- Registry status
- Phase 3
- Development phase
- 720 participants
- Enrollment target
Study Summary
The purpose of the study is to determine the best treatment approach based on the risk profile of the cancer cells and on how the disease responds to treatment. This is a randomized research study evaluating treatment for transplant-eligible participants with newly diagnosed multiple myeloma. Induction therapy in this study includes the drugs isatuximab, iberdomide, bortezomib, and dexamethasone. After induction therapy, participants will receive consolidation and maintenance therapy that is adapted based on their risk profile and response to treatment. The research study procedures include: screening for eligibility, study visits, blood and bone marrow tests, disease assessments, treatment with study drugs, and follow-up visits. It is expected that about 720 participants will take part in this study.
Interventions
- DRUG Melphalan
- DRUG Dexamethasone
- DRUG Isatuximab
- DRUG Iberdomide
- DRUG Bortezomib (B)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 720 participants |
| Start Date | 2026-06-08 |
| Est. Completion | 2038-03-01 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07624513
The ClinicalTrials.gov registry entry for NCT07624513 describes a study currently listed as not yet recruiting, categorized as Phase 3. The registered enrollment target is 720 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Dana-Farber Cancer Institute, which has 781 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which Melphalan is the first listed.
NCT07624513 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT07624513 about?
NCT07624513 is a clinical study titled "Determination 2 - Isatuximab, Iberdomide, Bortezomib and Dexamethasone Induction, Followed by Risk- and Response-Adapted Consolidation and Maintenance Therapy, in Transplant-Eligible Patients With Newly Diagnosed Multiple Myeloma". The purpose of the study is to determine the best treatment approach based on the risk profile of the cancer cells and on how the disease responds to treatment. This is a randomized research study evaluating treatment for transplant-eligible participants with newly diagnosed multiple myeloma. Induct...
What is the current status of trial NCT07624513?
This trial is currently not yet recruiting. It is a Phase 3 study. The enrollment target is 720 participants. The study started on 2026-06-08. Estimated completion is 2038-03-01.
What interventions are being tested in trial NCT07624513?
The interventions under investigation include: Melphalan (DRUG), Dexamethasone (DRUG), Isatuximab (DRUG), Iberdomide (DRUG), Bortezomib (B) (DRUG).
Who is sponsoring clinical trial NCT07624513?
This trial is sponsored by Dana-Farber Cancer Institute, which has 781 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.